DFTX
DFTX
NASDAQ · Pharmaceuticals

Definium Therapeutics Inc

Mid-Cap Stocks Pharmaceutical Stocks Healthcare Stocks
$22.05
-1.15 (-4.96%)
As of May 10, 10:06 PM ET ·
DFTX News1 articles
Definium's Psychedelic Drug DT120 Gains Analyst Backing Ahead of Key 2026 Data
Definium Therapeutics advanced after Stifel and Piper Sandler issued Buy ratings, spotlighting its LSD-based drug DT120 in late-stage trials for anxiety and depression. The company will host an investor day on April 22 to discuss upcoming Phase 3 data expected through 2026.
Analysis